NCT04183166 — Transgene TG4050 neoantigen vaccine trial
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
TG4050, Transgene + NEC — adjuvant head & neck cancer
Registry record
| Registry ID | NCT04183166 ↗ |
|---|---|
| Lead sponsor | Transgene |
| Collaborators | — |
| Phase | Phase 1/2 |
| Status | Active Not Recruiting |
| Indication | Squamous Cell Carcinoma of Head and Neck |
| Enrollment | 80 participants (target) |
| Start date | 2019-12-12 |
| Primary completion | 2027-12-30 (est.) |
| Last registry update | 16 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04183166), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
FAQ
What phase is NCT04183166?
NCT04183166 (A Clinical Trial Evaluating TG4050 in Head and Neck Cancer) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Transgene.
Is NCT04183166 recruiting?
As of the 2026-01-16 registry update, NCT04183166 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04183166?
The lead sponsor is Transgene.
What condition does NCT04183166 study?
The registered condition is Squamous Cell Carcinoma of Head and Neck. Primary completion is listed as 2027-12-30 (estimated).
Are results available for NCT04183166?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04183166.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.